Peanut Allergy Pipeline Insights, 2019 Report - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 23, 2019--The “Peanut Allergy - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
“Peanut Allergy - Pipeline Insight, 2019” report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Peanut Allergy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Peanut Allergy
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Peanut Allergy
The report assesses the active Peanut Allergy pipeline products by developmental stage, product type, molecule type, and administration route.
Scope of the reportThe report provides a snapshot of the pipeline development for the Peanut Allergy The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Peanut Allergy The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Peanut Allergy The report also covers the dormant and discontinued pipeline projects related to the Peanut Allergy
Key Topics Covered:
1. Report Introduction
2. Peanut Allergy Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
Companies MentionedAdverum Biotechnologies Inc Aimmune Therapeutics Inc Alfacyte Ltd Allergy Therapeutics Plc AnaptysBio Inc ASIT Biotech SA Astellas Pharma Inc BioLingus AG DBV Technologies SA HAL Allergy BV
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/kltvwz/peanut_allergy?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190123005354/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Allergy Drugs
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/23/2019 05:56 AM/DISC: 01/23/2019 05:56 AM